Instructions for use: Tikozide solution for injection 2 mg/ml ampoule 2 ml No. 6
Composition
active ingredient: thiocolchicoside;
1 ampoule (2 ml) contains thiocolchicoside 4 mg;
Excipients: sodium chloride, diluted hydrochloric acid, water for injections.
Dosage form
Solution for injection.
Main physicochemical properties: transparent solution of light yellow color.
Pharmacotherapeutic group
Muscle relaxants with a central mechanism of action. ATC code M0ZV X05.
Pharmacological properties
Pharmacodynamics.
Thiocolchicoside is a semisynthetic sulfide derivative of colchicoside that has a muscle relaxant effect.
In in vitro studies, thiocolchicoside binds only to GABA and strychnine-sensitive glycine receptors. Thiocolchicoside exhibits selective affinity for GABA receptors, causing an effective muscle relaxant effect through regulatory complex mechanisms at different levels of the nervous system, however, its glycinergic mechanism of action cannot be excluded.
The interaction characteristics of thiocolchicoside with GABA receptors are the same as those of its glucuronide derivative, which is the main metabolite (see below).
In in vivo studies, the muscle relaxant properties of thiochlorgicoside and its main metabolite have been demonstrated in various experimental models.
Electroencephalographic studies also showed that thiocolchicoside and its main metabolite do not cause a sedative effect.
Pharmacokinetics.
Absorption.
After intramuscular administration, the maximum plasma concentration (Cmax) of thiocolchicoside is observed after 30 minutes, with values of 113 ng/ml achieved after a 4 mg dose and 175 ng/ml after an 8 mg dose. The corresponding area under the pharmacokinetic curve (AUC) values are 283 and 417 ng∙g/ml.
The pharmacologically active metabolite SL18.0740 is also observed at lower concentrations, with a Cmax of 11.7 ng/mL, which is reached 5 hours after dosing, and an AUC of 83 ng∙g/mL.
There are no data on the inactive metabolite SL59.0955.
Distribution.
The apparent volume of distribution of thiocolchicoside is approximately 42.7 L after intramuscular administration of 8 mg. Data are not available for either metabolite.
Breeding.
The half-life of thiocolchicoside is 1.5 hours, and the plasma clearance is 19.2 l/h.
Indication
Adjunctive therapy for painful muscle contractures in cases of acute spinal pathologies in adults and adolescents aged 16 years and older.
Contraindication
- Hypersensitivity to the active substance or to any of the excipients of the medicinal product;
- flaccid paralysis, muscle hypotension;
- pregnancy;
- breastfeeding period;
- use in women of reproductive age who are not using adequate contraception.
Interaction with other medicinal products and other types of interactions
There is no information on interaction.
Application features
Vasovagal syncope has been reported following intramuscular injection of thiocolchicoside, therefore the patient should be monitored after administration of the medicinal product (see section 4.8).
In the post-marketing period, liver injury has been reported in connection with the use of thiocolchicoside. Severe cases (e.g. fulminant hepatitis) of liver injury have been reported in patients who were concomitantly taking non-steroidal anti-inflammatory drugs or paracetamol. If signs of liver injury develop during use of the drug, treatment should be discontinued and a doctor should be consulted (see section "Adverse reactions").
During the use of thiocolchicoside, epileptic seizures may develop in patients suffering from epilepsy or diseases accompanied by a risk of seizures (see section "Adverse reactions").
The maximum recommended dose of thiocolchicoside of 8 mg per day should not be exceeded, which should be divided into 2 doses with an interval of 12 hours. If a dose is missed, the next dose should be administered at the usual time.
According to preclinical studies, one of the metabolites of thiocolchicoside SL59.0955 causes aneuploidy (changes in the number of chromosomes in dividing cells) at concentrations close to 8 mg twice daily when administered orally, which had similar effects in humans.
Aneuploidy is considered a risk factor for teratogenicity, embryo/fetal toxicity, miscarriage, altered male fertility and a potential risk factor for cancer. As a precaution, exceeding the recommended dose of the drug or prolonged use should be avoided (see section "Dosage and Administration").
Patients should be well informed about the potential risks to possible pregnancy and about the effective contraceptive methods that should be used.
This medicinal product contains less than 1 mmol (23 mg) sodium/dose, i.e. essentially sodium-free.
Use during pregnancy or breastfeeding
Information on the use of thiocolchicoside in pregnant women is limited, therefore the potential risk to the embryo and fetus is unknown. Animal studies have shown teratogenic effects of thiocolchicoside. The drug is contraindicated for use during pregnancy and in women of childbearing potential not using adequate contraception (see section "Contraindications").
Breastfeeding period.
Thiocolchicoside passes into breast milk. The drug is contraindicated for use during breastfeeding (see section "Contraindications").
Fertility.
Fertility studies in animals have shown no changes in fertility at doses up to 12 mg/kg, i.e. at doses that did not cause clinical effects. Thiocolchicoside and its metabolites are aneugenic at various concentration levels, which is a risk factor for human fertility.
Ability to influence reaction speed when driving vehicles or other mechanisms
Studies of the effect of thiocolchicoside on the ability to drive vehicles or other mechanisms have not been conducted.
During the use of thiocolchicoside, drowsiness may develop, which should be taken into account when driving or operating other mechanisms.
Method of administration and doses
The drug is intended for intramuscular administration.
The recommended maximum daily dose is 4 mg every 12 hours (8 mg per day).
Treatment should not exceed 5 consecutive days.
Exceeding the recommended dose or duration of use should be avoided (see section "Special precautions for use").
Children.
The drug is contraindicated for use in children under 16 years of age.
Overdose
There are no data on cases of overdose. In case of overdose of the drug, careful medical supervision of the patient and symptomatic therapy are recommended.
Side effects
The following adverse reactions are listed by MedDRA system organ class and frequency: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (<1/10,000), not known (frequency cannot be estimated from the available data).
On the part of the immune system:
uncommon - itching; rare - urticaria; very rare - hypotension; unknown - angioedema and anaphylactic reactions, including anaphylactic shock.
From the nervous system:
Common: drowsiness; rare: agitation or short-term confusion; not known: malaise, with or without vasovagal syncope, within the first few minutes after intramuscular injection; convulsions (see section "Special warnings and precautions for use").
From the digestive tract:
often - diarrhea, stomach pain; infrequently - nausea, vomiting; rarely - heartburn.
From the hepatobiliary system:
frequency unknown – liver damage (see section "Special warnings and precautions for use").
Skin and subcutaneous tissue disorders:
infrequently - allergic skin reactions.
Reporting of suspected adverse reactions.
Reporting adverse reactions after the registration of a medicinal product is important. This allows monitoring of the benefit/risk ratio when using this medicinal product. Medical and pharmaceutical professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and lack of efficacy of the medicinal product via the Automated Information System for Pharmacovigilance at the link: https://aisf.dec.gov.ua.
Expiration date
3 years.
Storage conditions
Store at a temperature not exceeding 25 °C in the original packaging and out of the reach of children.
Packaging
2 ml in an ampoule; 6 ampoules in a contour blister pack; 1 contour blister pack in a cardboard box.
Vacation category
According to the recipe.
Producer
WORLD MEDICINE ILACH SAN. VE TIJ. A.Sh./
WORLD MEDICINE ILAC SAN. VE TIC. AS
Location of the manufacturer and address of its place of business.
OPZCH, G.O.Pasha Quarter, 6th Street, No. 30, Cherkezkoy/Tekirdag, Turkey/
COSB GOPasa Mah. 6. Cad. No:30, Cerkezkoy/Tekirdag, Turkey.
Applicant.
LLC "WORLD MEDICINE", Ukraine/
WORLD MEDICINE, LLC, Ukraine.
